Sun Pharma vs. Hetero Healthcare
Introduction Under Class 5 of the Trade Marks Act, 1999, Sun Pharma has registered the mark “LETROZ,” which refers to a medication used to treat advanced breast cancer. “LETROZOLE” is one of its active ingredients. Sun Pharma sued Hetero Healthcare Ltd. for using the mark “LETERO” on the basis of trademark infringement and passing off. … Continue reading Sun Pharma vs. Hetero Healthcare
Read more »Sun Pharmaceuticals v. Eli Lilly: Doctrine of Obviousness-Type Double Patenting
A remarkable latest change in the Patentability has risen from the decision of the Federal Circuit in the case Sun Pharmaceuticals v. Eli Lilly, over the later’s patent that claimed the use of gemcitabine (GEMZAR), a drug to treat cancer. Sun Pharma moved to lower court to invalidate this patent on the grounds of obviousness-type … Continue reading Sun Pharmaceuticals v. Eli Lilly: Doctrine of Obviousness-Type Double Patenting
Read more »Eli Lilly Vs Sun Pharma and others
Lilly’s Patent relates to method of treating Attention-Deficit/ Hyperactivity disorder (ADHD) with administration of effective amount of Tomoxetine. Lilly markets atomoxetine capsule under the brand name STRATTERA®. The US Patent 5,658,590 was assigned to Lilly On August 19, 1997 with a principal claim that recites a particular method of treating ADHD. Submission of an Abbreviated … Continue reading Eli Lilly Vs Sun Pharma and others
Read more »